Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment-Reference-Cited by-同舟云学术

Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment

Published:2014-11-01 Issue:11 Volume:132 Page:1327
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Geloneck Megan M.¹,Chuang Alice Z.¹,Clark W. Lloyd²,Hunt Michael G.³,Norman Alan A.³,Packwood Eric A.³,Tawansy Khaled A.⁴,Mintz-Hittner Helen A.¹

Affiliation:

1. Ruiz Department of Ophthalmology and Visual Science, The University of Texas Health Science Center–Houston Medical School, Houston

2. Neonatal Intensive Care Unit, Palmetto Health Baptist Medical Center, Columbia, South Carolina3Neonatal Intensive Care Unit, Palmetto Health Richland Medical Center, Columbia, South Carolina

3. Neonatal Intensive Care Unit, Cook Children’s Medical Center, Ft Worth, Texas

4. Neonatal Intensive Care Unit, Huntington Memorial Hospital, Pasadena, California

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Cited by 282 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Six years follow-up of type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab and bevacizumab: Long-Term Outcomes of intravitreal injection in Type 1 ROP;Medicine;2024-08-09

2. Safety and efficacy of ripasudil eye drops in preterm infants with retinopathy of prematurity: phase 1/2, open label, single-arm trial;Japanese Journal of Ophthalmology;2024-07-26

3. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial;eClinicalMedicine;2024-05

4. Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity;JAMA Network Open;2024-04-30

5. Intravitreal ranibizumab in aggressive retinopathy of prematurity compared with type 1 retinopathy of prematurity in Egyptian preterm infants (non-randomized clinical trial);2024-04-10